Novo Nordisk Total Non-Operating Income/Expense 2010-2024 | NVO
Novo Nordisk annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Novo Nordisk total non-operating income/expense for the quarter ending December 31, 2024 was $-0.173B, a 241.21% decline year-over-year.
- Novo Nordisk total non-operating income/expense for the twelve months ending December 31, 2024 was $-0.166B, a 154.59% decline year-over-year.
- Novo Nordisk annual total non-operating income/expense for 2024 was $-0.166B, a 154.59% decline from 2023.
- Novo Nordisk annual total non-operating income/expense for 2023 was $0.305B, a 137.47% decline from 2022.
- Novo Nordisk annual total non-operating income/expense for 2022 was $-0.814B, a 1273.13% decline from 2021.
Novo Nordisk Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2024 |
$-166 |
| 2023 |
$305 |
| 2022 |
$-814 |
| 2021 |
$69 |
| 2020 |
$-153 |
| 2019 |
$-589 |
| 2018 |
$56 |
| 2017 |
$-44 |
| 2016 |
$-94 |
| 2015 |
$-887 |
| 2014 |
$-71 |
| 2013 |
$186 |
| 2012 |
$-287 |
| 2011 |
$-84 |
| 2010 |
$-108 |
| 2009 |
$-177 |
Novo Nordisk Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-12-31 |
$-173 |
| 2024-09-30 |
$83 |
| 2024-06-30 |
$-87 |
| 2024-03-31 |
$10 |
| 2023-12-31 |
$122 |
| 2023-09-30 |
$168 |
| 2023-06-30 |
$53 |
| 2023-03-31 |
$-39 |
| 2022-12-31 |
$-109 |
| 2022-09-30 |
$-291 |
| 2022-06-30 |
$-228 |
| 2022-03-31 |
$-185 |
| 2021-12-31 |
$-86 |
| 2021-09-30 |
$-22 |
| 2021-06-30 |
$22 |
| 2021-03-31 |
$155 |
| 2020-12-31 |
$117 |
| 2020-09-30 |
$-18 |
| 2020-06-30 |
$-62 |
| 2020-03-31 |
$-189 |
| 2019-12-31 |
$-116 |
| 2019-09-30 |
$-121 |
| 2019-06-30 |
$-197 |
| 2019-03-31 |
$-155 |
| 2018-12-31 |
$-77 |
| 2018-09-30 |
$-105 |
| 2018-06-30 |
$47 |
| 2018-03-31 |
$192 |
| 2017-12-31 |
$70 |
| 2017-09-30 |
$66 |
| 2017-06-30 |
$-110 |
| 2017-03-31 |
$-70 |
| 2016-12-31 |
$-40 |
| 2016-09-30 |
$-18 |
| 2016-06-30 |
$16 |
| 2016-03-31 |
$-53 |
| 2015-12-31 |
$-117 |
| 2015-09-30 |
$-275 |
| 2015-06-30 |
$-287 |
| 2015-03-31 |
$-208 |
| 2014-12-31 |
$-146 |
| 2014-09-30 |
$-20 |
| 2014-06-30 |
$47 |
| 2014-03-31 |
$49 |
| 2013-12-31 |
$78 |
| 2013-09-30 |
$55 |
| 2013-06-30 |
$17 |
| 2013-03-31 |
$37 |
| 2012-12-31 |
$-22 |
| 2012-09-30 |
$-85 |
| 2012-06-30 |
$-123 |
| 2012-03-31 |
$-58 |
| 2011-12-31 |
$-90 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$39 |
| 2011-03-31 |
$-23 |
| 2010-12-31 |
$-29 |
| 2010-09-30 |
$-62 |
| 2010-06-30 |
$-47 |
| 2010-03-31 |
$30 |
| 2009-12-31 |
$-68 |
| 2009-09-30 |
$-33 |
| 2009-06-30 |
$-38 |
| 2009-03-31 |
$-38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$311.614B |
$42.122B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
